Sumitomo Dainippon Pharma and Exscientia achieve breakthrough in AI drug discovery

Japanese giant Sumitomo Dainippon Pharma and Oxford-headquartered AI-driven drug discovery company Exscientia yesterday announced that they have created a new compound which is in the process of entering human clinical trials in Japan. This is the first time a new precision engineered drug generated by AI is entering Phase 1 human clinical trials.

Powered by WPeMatico